This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Pediatric Ophthalmology  • Retinal/ Chorioretinal Disorders  • Pediatrics  • Pediatrics, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Sun Young Lee, MD; Dong-Kyu Kim, DVM; Jae Hyung Cho, MD; Jae-Young Koh, MD, PhD; Young Hee Yoon, MD

Arch Ophthalmol. 2008;126(7):953-958.

Objective  To evaluate the potential effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), on the angiogenesis and tumor growth of retinoblastoma in vitro and in vivo.

Methods  The antiangiogenic effects of bevacizumab were evaluated in a coculture of a Y-79 human retinoblastoma cell line and a human umbilical vein endothelial cell line by means of a cell proliferation assay kit and a VEGF enzyme-linked immunosorbent assay. The Y-79 xenotransplanted nude mice were treated with bevacizumab intraperitoneally twice weekly for 4 weeks, during which each tumor was measured once a week. The mice were then euthanized, and the weight of each tumor and its microvessel density were determined via CD34 immunohistochemical staining.

Results  The mean (standard error of the mean) increased human umbilical vein endothelial cell proliferation, when cocultured with Y-79 (156% [1%]), was suppressed 58% (5%) by the blockage of VEGF induced by bevacizumab. By causing a 2-fold reduction in microvessel density in the Y-79 xenograft model, bevacizumab induced a 75% reduction in the growth of the retinoblastomas without producing significant systemic toxicity.

Conclusions and Clinical Relevance  Treatment with bevacizumab suppressed the angiogenesis and growth of retinoblastoma in vitro and in vivo. Bevacizumab is likely to be of benefit in the treatment of retinoblastoma.

Author Affiliations: Departments of Ophthalmology (Drs Lee and Yoon) and Neurology (Dr Koh), and the Neural Injury Research Laboratory (Drs Kim, Cho, and Koh), University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes
Sakurai et al.
IOVS 2009;50:4905-4916.
ABSTRACT | FULL TEXT